Dr. Catenacci is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
5841 S. MARYLAND
M/C 2115
Chicago, IL 60637Phone+1 773-702-7596Fax+1 773-702-9268- Is this information wrong?
Summary
- Dr. Daniel Catenacci is an oncologist in Chicago, IL and is affiliated with University of Chicago Medical Center. He received his medical degree from Wayne State University School of Medicine and has been in practice 14 years. He specializes in gastrointestinal cancer and hematologic oncology and is experienced in gi medical oncology.
Education & Training
University of ChicagoMSc, Health Studies, 2011
University of ChicagoFellowship, Hematology and Medical Oncology, 2006 - 2010
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 2003 - 2006
Wayne State University School of MedicineClass of 2003- University of WaterlooBSc, With Honors, 1995 - 1999
Certifications & Licensure
CA State Medical License 2005 - Present
IL State Medical License 2006 - 2026
Awards, Honors, & Recognition
- Best Abstract Translational Research Faculty Category Annual Janet Rowley Research Day, University of Chicago, 2014
- K23 Scholar University of Chicago Medical Center, 2014
- Best Abstract and Oral Presentation 5th Annual WIN (Worldwide Innovative Networking in Personalized Cancer Medicine) Symposium, 2013
- Join now to see all
Clinical Trials
- Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery Start of enrollment: 2009 Oct 28
- Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Start of enrollment: 2010 Feb 15
- Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Surgery or Biopsy Start of enrollment: 2008 Jul 02
- Join now to see all
Publications & Presentations
PubMed
- 16 citationsAnalysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric Cancers.Brandon M Huffman, Vasily N Aushev, Griffin L Budde, Joseph Chao, Farshid Dayyani, Diana Hanna, Gregory P Botta, Daniel V T Catenacci, Steven B Maron, Shifra Krinshpun...> ;JCO Precision Oncology. 2022 Dec 1
- ACR Appropriateness Criteria® Staging and Follow-Up of Esophageal Cancer., Constantine A Raptis, Alan Goldstein, Travis S Henry, Kristin K Porter, Daniel Catenacci, Aine Marie Kelly, Christopher T Kuzniewski, Andrew R Lai, Elizabeth Lee, Ja...> ;Journal of the American College of Radiology. 2022 Nov 1
- 44 citationsBemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 s...Zev A Wainberg, Peter C Enzinger, Yoon-Koo Kang, Shukui Qin, Kensei Yamaguchi, In-Ho Kim, Anwaar Saeed, Sang Cheul Oh, Jin Li, Haci Mehmet Turk, Alexandra Teixeira, Ch...> ;The Lancet. Oncology. 2022 Nov 1
- Join now to see all
Journal Articles
- Author Correction: Targeting Wild-Type KRAS-Amplified Gastroesophageal Cancer Through Combined MEK and SHP2 InhibitionDaniel Catenacci, Adam J Bass, Shaunt Fereshetian, Rameen Beroukhim, Nature
- The Expansion Platform Type II Design: Testing a Treatment StrategyCatenacci DVT, Lancet Oncology, 1/8/2015
- A randomized pilot phase I study of modified Carcinoembryonic antigen (CEA) peptide (CAP1-6D)/Montanide/GM-CSF-vaccine (CEA-vac) in patients (pts) with pancreatic aden...Geynisman DM, Zha Y, Kunnavakkam R, Aklilu D, Catenacci DVT, Polite BN, Rosenbaum A, Namakydoust A, Karrison T, Gajewski TF, Kindler HL, Journal for ImmunoTherapy of Cancer, 1/1/2013
Books/Book Chapters
Abstracts/Posters
- KRAS gene amplification defines a distinct molecular subgroup of gastroesophageal adenocarcinoma.Henderson L, Xu P, O’Day E, Cecchi F, Blackler A, Liao WL, Hembrough T, Catenacci DVT, GI ASCO 2016, San Francisco, CA, 1/1/2016
- Evaluation of MET as a Prognostic Biomarker Determined by FISH, IHC, or Mass Spectrometry in Patients With Gastroesophageal Cancer.Catenacci DVT, Shen J, Liao WL, Oliner KS, Ang A, Loberg R, O’Day E, Xu P, Henderson L, Cecchi F, Burrows J, Hembrough T, Ruzzo A, Graziano F, ECC/ESMO, Vienna, Austria, 1/28/2015
- Phase 3, randomized, double-blind, multicenter, placebo-controlled trial of rilotumumab (R) plus epirubicin, cisplatin, and capecitabine (ECX) as first-line therapy in...Cunningham D, Tebbutt NC, Davidenko I, Murad AM, Al-Batran S, Ilson DH, Tjulandin S, Gotovkin E, Karaszewska B, Bondarenko I, Tejani M, Udrea AA, Baker N, Oliner KS, Z..., ASCO, Chicago, IL, 1/1/2015
- Join now to see all
Lectures
- Personalized ANtibodies for GastroEsophageal Adenocarcinoma (PANGEA): Primary efficacy analysis of the phase II platform trial (NCT02213289).ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/23/2020
- Margetuximab (M) combined with anti-PD-1 (MGA012) or anti-PD-1/LAG-3 (MGD013) +/- chemotherapy (CTX) in first-line therapy of advanced/metastatic HER2+ gastroesophagea...ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/23/2020
- Perioperative (P) UGT1A1 genotype guided irinotecan (iri) dosing ‘gFOLFIRINOX’ for gastroesophageal adenocarcinoma (GEA).2019 ASCO Annual Meeting - 6/1/2019
- Join now to see all
Authored Content
- What Does the the Javelin Gastric 100 Phase III Global Randomized Study Add to Research?February 2020
- What Does the the Javelin Gastric 100 Phase III Global Randomized Study Add to Research?February 2020
Press Mentions
Tumor Signature Better Predicts Gastric Cancer Prognosis Than Current Staging SystemDecember 2nd, 2021- Are Liquid Biopsies Ready for the Clinic?December 18th, 2020
- Gritstone Oncology Advances into Phase 2 Expansion Cohorts for Its Personalized Neoantigen Immunotherapy GRANITE and Its Off-the-Shelf Neoantigen Immunotherapy SLATENovember 2nd, 2020
- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
University of Chicago Medical CenterChicago, Illinois
External Links
- PANGEAhttp://ecancer.org/video/2151/strategies-to-address-inter--and-intra--patient-tumour-heterogeneity--pangea.php
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
